DUBLIN, Ireland – Two days after the board of Elan Corp. plc unanimously rejected Royalty Pharma's $7.3 billion takeover offer, CEO Kelly Martin set out, as best he could, the contours of the company's M&A strategy during a first-quarter results call with analysts last week.